Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 58
    records per page




    Clinical-epidemiological and treatment characteristics of children TRANS with COVID-19 in a tertiary referral center in Peru

    Authors: Christian Chiara-Chilet; Medalit Luna-Vilchez; Julio Maquera-Afaray; Blanca Salazar-Mesones; Diana Portillo-Alvarez; Ramiro Priale-Miranda; Franklin Mendoza-Torres; Aldo Munayco-Perez; Yeny Baca-Cama; Mitsi Santiago-Abad; Jose W Lopez; - Pediatric COVID-19 Working Group INSN SB; Alexandra Trkola; Jan Fehr; Milo A Puhan; Susi Kriemler; Peter Hau; Christopher Bohr; Ralph Burkhardt; Andre Gessner; Bernd Salzberger; Frank Hanses; Florian Hitzenbichler; Daniel Heudobler; Florian Lueke; Tobias Pukrop; Wolfgang Herr; Daniel Wolff; Hendrik Poeck; Christoph Brochhausen; Petra Hoffmann; Michael Rehli; Marina Kreutz; Kathrin Renner

    doi:10.1101/2020.09.18.20186866 Date: 2020-09-18 Source: medRxiv

    Introduction The COVID-19 pandemic has a great impact on children TRANS's health. This study describes the clinical, epidemiological and treatment characteristics of children TRANS presenting COVID-19 at the Instituto Nacional de Salud del Nino San Borja (INSN-SB) Methods This was a retrospective study of patients with a confirmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological, and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine differences between patients in general wards and the intensive care unit (ICU). Results We included 91 patients, 33 being females TRANS (36.3%). The most affected age group TRANS was children TRANS > 2 years of age TRANS (63 cases) with a median age TRANS of 6 years (IQR 3-10), and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever HP (39.6%), general malaise (23.1%), cough HP (19.8%), and respiratory distress HP (14.3%). The presence of multisystem inflammatory syndrome MESHD in children TRANS (MIS-C) was confirmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern was bilateral interstitial infiltrates (57.7%). Mortality was higher in patients in the ICU than in the hospitalization ward (27.3% vs. 4.3%, respectively; p = 0.02) Conclusions COVID-19 in children TRANS presents mild and moderate clinical manifestations. The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care units.

    Risk Factors Analysis of COVID-19 Patients with ARDS MESHD and Prediction Based on Machine Learning

    Authors: Wan Xu; Nan-Nan Sun; Hai-Nv Gao; Zhi-Yuan Chen; Ya Yang; Bin Ju; Ling-Ling Tang

    doi:10.21203/rs.3.rs-77820/v1 Date: 2020-09-15 Source: ResearchSquare

    COVID-19 is a newly emerging infectious disease MESHD, which is generally susceptible to human beings and has caused huge losses to people's health. Acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD) is one of the common clinical manifestations of severe COVID-19 and it is also responsible for the current shortage of ventilators worldwide. This study aims to analyze the clinical characteristics of COVID-19 ARDS MESHD patients and establish a diagnostic system based on artificial intelligence (AI) method to predict the probability of ARDS in COVID-19 patients. We collected clinical data of 659 COVID-19 patients from 11 regions in China. The clinical characteristics of the two groups were elaborately compared and both traditional machine learning algorithms MESHD and deep learning-based methods were used to build the prediction models. Results indicated the median age TRANS of ARDS MESHD patients was 56.5 years old, which was significantly older than those with non-ARDS by 7.5 years. Male TRANS and patients with BMI>25 were more likely to develop ARDS MESHD. The clinical features of ARDS MESHD patients included cough HP (80.3%), polypnea (59.2%), lung consolidation (53.9%), secondary bacterial infection MESHD (30.3%), and comorbidities such as hypertension HP hypertension MESHD (48.7%). Abnormal biochemical indicators such as lymphocyte count, leukocyte counting, CK, NLR, AST, LDH, and CRP were all strongly related to the aggravation of ARDS. Furthermore, through various AI methods for modeling and prediction effect evaluation based on the above risk factors, decision tree achieved the best AUC, sensitivity SERO, and specificity in identifying the mild patients who were easy to develop ARDS MESHD, which undoubtedly helps to optimize the treatment strategy, reduce mortality, and relieve the medical pressure. 

    G6PD deficiency MESHD and severity of COVID19 pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome: tip of the iceberg?

    Authors: Jihad G. Youssef; Faisal Zahiruddin; George Youssef; Sriram Padmanabhan; Joe Ensor; Sai Ravi Pingali; Youli Zu; Sandeep Sahay; Swaminathan P. Iyer

    doi:10.21203/rs.3.rs-72639/v1 Date: 2020-09-05 Source: ResearchSquare

    The severe pneumonia HP pneumonia MESHD caused by human coronavirus (hCoV)-SARS-CoV-2 has inflicted heavy causalities, especially among the elderly TRANS and those with comorbid illnesses irrespective of age TRANS. The high mortality in African Americans and males TRANS, in general, raises concern for a possible X-linked mediated process that could affect viral pathogenesis and the immune system. We hypothesized that G6PD, the most common X-linked enzyme deficiency MESHD associated with redox status, may have a role in the severity of pneumonia HP pneumonia MESHD. A retrospective chart review was performed in hospitalized patients with COVID19 pneumonia HP pneumonia MESHD needing supplemental oxygen. A total of 17 patients were evaluated: six with G6PD deficiency MESHD and 11 with normal levels. The two groups (normal and G6PD def) were comparable in terms of age TRANS, sex and comorbidities and laboratory parameters LDH, IL-6, CRP, and ferritin. Thirteen patients needed ventilatory support, with 6 in the G6PD group (83% vs. 72%). The main differences indicating increasing severity in the G6PD def group included G6PD levels (12.2 vs. 5.6, P=0.0002), PaO2/FiO2 ratio (159 vs. 108, P=0.05), days before intubation (2.5 vs. 4.8 P= 0.03), days on mechanical ventilation (10.25 vs. 21 days P=0.04), hemoglobin level (10 vs. 8.1 P=0.03) and hematocrit (32 vs. 26 P=0.015). Only one patient with G6PD deficiency MESHD died; 16 were discharged home. Our clinical series ascribes a possible biological role for G6PD deficiency MESHD in SARS-CoV2 viral proliferation. It is imperative that further studies be performed to understand the interplay between the viral and host factors in G6PD deficiency MESHD that may lead to disparity in outcomes. 

    Machine Learning and Meta-Analysis Approach to Identify Patient Comorbidities and Symptoms that Increased Risk of Mortality in COVID-19

    Authors: Sakifa Aktar; Ashis Talukder; Md. Martuza Ahamad; A. H. M. Kamal; Jahidur Rahman Khan; Md. Protikuzzaman; Nasif Hossain; Julian M. W. Quinn; Mathew A. Summers; Teng Liaw; Valsamma Eapen; Mohammad Ali Moni

    id:2008.12683v1 Date: 2020-08-21 Source: arXiv

    Background: Providing appropriate care for people suffering from COVID-19, the disease caused by the pandemic SARS-CoV-2 virus is a significant global challenge. Many individuals who become infected have pre-existing conditions that may interact with COVID-19 to increase symptom severity and mortality risk. COVID-19 patient comorbidities are likely to be informative about individual risk of severe illness and mortality. Accurately determining how comorbidities are associated with severe symptoms and mortality would thus greatly assist in COVID-19 care planning and provision. Methods: To assess the interaction of patient comorbidities with COVID-19 severity and mortality we performed a meta-analysis of the published global literature, and machine learning predictive analysis using an aggregated COVID-19 global dataset. Results: Our meta-analysis identified chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD ( COPD MESHD), cerebrovascular disease MESHD ( CEVD MESHD), cardiovascular disease MESHD ( CVD MESHD), type 2 diabetes MESHD, malignancy MESHD, and hypertension HP hypertension MESHD as most significantly associated with COVID-19 severity in the current published literature. Machine learning classification using novel aggregated cohort data similarly found COPD MESHD, CVD MESHD, CKD, type 2 diabetes MESHD, malignancy MESHD and hypertension HP hypertension MESHD, as well as asthma HP, as the most significant features for classifying those deceased versus those who survived COVID-19. While age TRANS and gender TRANS were the most significant predictor of mortality, in terms of symptom-comorbidity combinations, it was observed that Pneumonia HP Pneumonia MESHD- Hypertension HP, Pneumonia HP Pneumonia MESHD-Diabetes and Acute Respiratory Distress HP Respiratory Distress MESHD Syndrome ( ARDS MESHD)- Hypertension HP Hypertension MESHD showed the most significant effects on COVID-19 mortality. Conclusions: These results highlight patient cohorts most at risk of COVID-19 related severe morbidity and mortality which have implications for prioritization of hospital resources.

    The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.

    Authors: Maria Mateos Gonzalez; Elena Sierra Gonzalo; Irene Casado Lopez; Francisco Arnalich Fernandez; Jose Luis Beato Perez; Daniel Monge Monge; Juan Antonio Vargas Nunez; Rosa Garcia Fenoll; Carmen Suarez Fernandez; Santiago Jesus Freire Castro; Manuel Mendez Bailon; Isabel Perales Fraile; Manuel Madrazo; Paula Maria Pesqueira Fontan; Jeffrey Oskar Magallanes Gamboa; Andres Gonzalez Garcia; Anxela Crestelo Vieitez; Eva Maria Fonseca Aizpuru; Asier Aranguren Arostegui; Ainara Coduras Erdozain; Carmen Martinez Cilleros; Jose Loureiro Amigo; Francisco Epelde; Carlos Lumbreras Bermejo; Juan Miguel Anton Santos

    doi:10.1101/2020.08.18.20172874 Date: 2020-08-21 Source: medRxiv

    Objectives: A decrease in blood SERO cell counts, especially lymphocytes and eosinophils, has been described in patients with severe SARS-CoV-2 (COVID-19), but there is no knowledge of the potential role of their recovery in these patients prognosis. This article aims to analyse the effect of blood SERO cell depletion and blood SERO cell recovery on mortality due to COVID-19. Design: This work is a multicentre, retrospective, cohort study of 9,644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine SEMI-COVID-19 Registry. Setting: This study examined patients hospitalised in 147 hospitals throughout Spain. Participants: This work analysed 9,644 patients (57.12% male TRANS) out of a cohort of 12,826 patients over 18 years of age TRANS hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. Main outcome measures: The main outcome measure of this work is the effect of blood SERO cell depletion and blood SERO cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death MESHD and then multivariate analysis was carried out to control for potential confounders. Results: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs 22.6% in non-recoverers, OR 0.234 [95% CI, 0.154 to 0.354]) and lower complication rates, especially regarding to development of acute respiratory distress syndrome MESHD respiratory distress HP syndrome (8% vs 20.1%, p=0.000) and ICU admission (5.4% vs 10.8%, p=0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor. Conclusion: Eosinophil recovery in patients with COVID-19 is a reliable marker of a good prognosis that is independent of prior treatment. This finding could be used to guide discharge decisions.

    Continuous extracorporeal treatments in a dialysis patient with COVID-19

    Authors: Yoshihito Nihei; Hajime Nagasawa; Yusuke Fukao; Masao Kihara; Seiji Ueda; Tomohito Gohda; Yusuke Suzuki

    doi:10.21203/rs.3.rs-63251/v1 Date: 2020-08-20 Source: ResearchSquare

    The coronavirus disease MESHD 2019 (COVID-19) pandemic is now a major global health threat. More than half a year have passed since the first discovery of severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV2), no effective treatment has been established especially in intensive care unit. Inflammatory cytokine storm caused by SARS-CoV-2 infection MESHD has been reported to play a central role in COVID-19; therefore, treatments for suppressing cytokines, including extracorporeal treatments, are considered to be beneficial. However, until today the efficacy of removing cytokines by extracorporeal treatments in patients with COVID-19 is unclear. We herein report our experience with a 66-year-old male TRANS patient undergoing maintenance peritoneal dialysis who became critically ill with COVID-19 and underwent several extracorporeal treatment approaches including plasma SERO exchange, direct hemoperfusion using a polymyxin B-immobilized fiber column and continuous hemodiafiltration. Though the patient developed acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) repeatedly and subacute cerebral infarction MESHD and finally died for respiratory failure HP respiratory failure MESHD on day 30 after admission, these attempts appeared to somewhat dampen the cytokine storm based on the observed decline in serum SERO IL-6 levels and were effective against ARDS MESHD and secondary haemophagocytic lymphohistiocytosis MESHD. This case suggests the significance of timely initiation of extracorporeal treatment approaches in critical ill patients with COVID-19.

    Continuous extracorporeal treatments in a dialysis patient with COVID-19

    Authors: Yoshihito Nihei; Hajime Nagasawa; Yusuke Fukao; Masao Kihara; Seiji Ueda; Tomohito Gohda; Yusuke Suzuki

    doi:10.21203/rs.3.rs-63251/v2 Date: 2020-08-20 Source: ResearchSquare

    The coronavirus disease MESHD 2019 (COVID-19) pandemic is now a major global health threat. More than half a year have passed since the first discovery of severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV2), no effective treatment has been established especially in intensive care unit. Inflammatory cytokine storm caused by SARS-CoV-2 infection MESHD has been reported to play a central role in COVID-19; therefore, treatments for suppressing cytokines, including extracorporeal treatments, are considered to be beneficial. However, until today the efficacy of removing cytokines by extracorporeal treatments in patients with COVID-19 is unclear. Herein, we report our experience with a 66-year-old male TRANS patient undergoing maintenance peritoneal dialysis who became critically ill with COVID-19 and underwent several extracorporeal treatment approaches including plasma SERO exchange, direct hemoperfusion using a polymyxin B-immobilized fiber column and continuous hemodiafiltration. Though the patient developed acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) repeatedly and subacute cerebral infarction MESHD and finally died for respiratory failure HP respiratory failure MESHD on day 30 after admission, these attempts appeared to dampen the cytokine storm based on the observed decline in serum SERO IL-6 levels and were effective against ARDS MESHD and secondary haemophagocytic lymphohistiocytosis MESHD. This case suggests the significance of timely initiation of extracorporeal treatment approaches in critically ill MESHD patients with COVID-19.

    Clinical characteristics and post-intensive care outcomes of COVID-19 pneumonia HP pneumonia MESHD.

    Authors: Neil MD Cody; Samuel M Lakey; Sean M McMahon; Megan K Downey; Megan S Duncan; Julie-Anne Hewitt; Calum B Simpson; Martin J Duffy; Rosalind F O’Reilly; Paul Johnston; Jonathan A Silversides; Belfast COVID ICU Group

    doi:10.21203/rs.3.rs-58685/v1 Date: 2020-08-13 Source: ResearchSquare

    Background: COVID-19 can result in a severe viral pneumonia MESHD pneumonia HP, with high reported mortality rates in patients requiring mechanical ventilation. There is controversy as to whether established therapeutic approaches to acute respiratory distress syndrome MESHD respiratory distress HP syndrome are optimal in this condition, and numerous novel therapies have been used, often outside the context of randomised trials. In addition, longer term quality of life outcomes associated with COVID-19 are as yet unknown. The aim of this case series is to describe demographic, physiological and outcome data of patients with COVID-19 admitted to our intensive care units who were treated according to evidence-based guidelines for acute respiratory distress syndrome MESHD respiratory distress HP syndrome.Methods: We retrospectively reviewed the records of all patients admitted to intensive care units in our institution with COVID-19 between March and June, 2020. Physiological and laboratory data were recorded at baseline and daily until intensive care discharge or death MESHD. Quality of life was assessed at a virtual post-intensive care follow-up clinic around 10 weeks after ICU discharge.Results: 45 patients with COVID-19 were included, 37 (82.2%) of whom were male TRANS, with a mean age TRANS of 55 years. 42 (93.3%) of this cohort met criteria for acute respiratory distress syndrome MESHD respiratory distress HP syndrome at time of admission. Clinical management was consistent with evidence based institutional guidelines introduced for acute respiratory distress syndrome MESHD respiratory distress HP syndrome. Median length of intensive care stay was 14 days. The intensive care mortality rate was 8.9%. Functional and psychological morbidity post intensive care was significant: 45.2% of respondents had at least moderate impairment of mobility and 35.5% described at least moderate symptoms of anxiety HP anxiety MESHD or depression MESHD at the time of follow up.Conclusions : This case series demonstrates low mortality in a cohort of patients treated according to an established evidence-based approach for acute respiratory distress syndrome MESHD respiratory distress HP syndrome. However, COVID-19 survivors have a marked functional and psychological morbidity impacting quality of life following ICU admission. The therapeutic goal in the future will be to achieve similar survival outcomes while minimizing the significant morbidity associated with COVID-19 related critical care admission.

    Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia

    Authors: Nancy Yomayusa; Kelly Rocío Chacón Acevedo; Adriana Janeth Avila Reina; Karen Lorena Rincón; Carlos Hernando Toloza; Olga Gomez Gomez; Eduardo Low Padilla; Juan Felipe Combariza Vallejo; Johana Vargas Rodriguez; Emilio Herrera Molina; Sandra Yadira Moreno Marin; Carlos Arturo Álvarez Moreno

    doi:10.21203/rs.3.rs-57978/v1 Date: 2020-08-12 Source: ResearchSquare

    Background: Coronavirus disease (COVID-19) represents an unprecedented challenge for both people and health systems. Latin America is the current epicentre of the pandemic; however, there is little published clinical information on the clinical characteristics and outcomes.Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection TRANS by COVID-19 in 5 Colombian institutions.Methods: In the present retrospective observational study, information was acquired from consecutive hospitalized patients with a diagnosis of COVID-19 confirmed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) from March 01 to May 30, 2020 in Colombia.Results: A total of 44 patients were included. The median age TRANS was 62 years, and 65.9% of the patients were male TRANS. A total of 69.8% of the patients were overweight HP or obese MESHD, and 13.6% of the patients had high blood SERO pressure and diabetes MESHD. The presence of systemic symptoms and cough HP cough MESHD were the most common. Ground-glass opacity was frequent finding upon chest imaging. The 30-day mortality rate was 47.7% with a median of 11 days. The composite outcome (critical care requirement, mechanical ventilation and death MESHD) occurred in 36.4% of the patients. The biomarkers associated with mortality risk included troponin higher than 14 ng/L (RR: 5.25; 95% CI 1.37-20.1, p = 0.004) and D-dimer higher than 1000 ng/ml (RR: 3.0; 95% CI 1.4-6.3, p = 0.008). Cardiovascular complications MESHD, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) and acute kidney injury HP acute kidney injury MESHD were the most frequent comorbidities in patients with severe pneumonia HP pneumonia MESHD.Conclusion: The clinical course of SARS-CoV-2 infection MESHD diagnosis confirmed by RT-PCR in Colombian patients admitted to a high-complexity hospital was similar to that reported in the literature; however, the population was characterised by a more advanced stage of the infection MESHD

    Clinical Determinants of the Severity of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis

    Authors: Yanling Wu; Hu Li; Shengjin Li

    doi:10.21203/rs.3.rs-56852/v1 Date: 2020-08-10 Source: ResearchSquare

    Background: SARS-CoV-2 is an emerging pathogen, and coronavirus disease MESHD 2019 (COVID-19) has been declared a global pandemic. We aim to summarize current evidence regarding the risk of death MESHD and the severity of COVID-19 as well as risk factors for severe COVID-19.Methods: The PubMed, Embase, and Web of Science databases as well as some Chinese databases were searched for clinical and epidemiological studies on COVID-19. We conducted a meta-analysis to examine COVID-19-related death MESHD and risk factors for the severity of COVID-19.Results: A total of 55 studies fulfilled the criteria for this review. The case fatality risk ranged from 0 to 61.5%, with a pooled estimate of 3.3%. The risks of ICU admission, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD)and severe COVID-19 were 24.9%, 20.9% and 26.6%, respectively. Factors related to the risk of severe COVID-19 were older age TRANS (MD=10.09, 95% CI:7.03, 13.16), male TRANS sex (OR=1.62, 95% CI:1.32, 1.99), hypertension HP hypertension MESHD (OR=2.34, 95% CI:1.47, 3.73), diabetes MESHD (OR=2.25, 95% CI:1.68, 3.03), chronic renal disease MESHD (OR=3.60, 95% CI:1.53, 8.46), heart disease MESHD (OR=2.76, 95% CI:1.78, 4.30), respiratory disease MESHD (OR=3.74, 95% CI:2.15, 6.49), cerebrovascular disease MESHD (OR=2.21, 95% CI:1.23, 3.98), higher D-dimer levels (SMD=0.62, 95% CI:0.28, 0.96), and higher IL-6 levels (SMD=2.21, 95% CI:0.11, 4.31). However, liver disease MESHD (OR=0.63, 95% CI: 0.36, 1.10) was found to be a nonsignificant predictor of the severity of COVID-19.Conclusions: The case fatality risk of COVID-19 and the risk of severe manifestations were not very high, and variances in the study designs and regions led to high heterogeneity among the studies. Male TRANS sex, older age TRANS, comorbidities such as hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular disease MESHD, respiratory disease MESHD and cerebrovascular disease MESHD could increase the risk of developing a severe case of COVID-19. Laboratory parameters, such as D-dimer and IL-6 levels, could affect the prognosis of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.